Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment

Journal of Bone and Mineral Metabolism

Volumn 29, Issue 1, 2011, Pages 62-70

  Shiraki, Masataka ^a   Kuroda, Tatsuhiko ^b   Shiraki, Yumiko ^a   Tanaka, Shiro ^c   Higuchi, Tsuyoshi ^d   Saito, Mitsuru ^e  

^a RESEARCH INSTITUTE AND PRACTICE FOR INVOLUTIONAL DISEASES   (Japan)

^b Nishiyama Kogyo Ochanomizu Building 5F   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d HIROSAKI UNIVERSITY   (Japan)

^e NONE

Author keywords

Bisphosphonates; Fracture; Homocysteine; Osteoporosis; Pentosidine

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CALCIUM; HOMOCYSTEINE; PENTOSIDINE; PHOSPHATE; RISEDRONIC ACID;

AGE; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; DIABETIC PATIENT; DISEASE PREDISPOSITION; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SPINE RADIOGRAPHY; URINARY EXCRETION; URINE LEVEL; VERTEBRA FRACTURE;

AGED; ARGININE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HOMOCYSTEINE; HUMANS; LYSINE; MIDDLE AGED; OSTEOPOROSIS; PROPORTIONAL HAZARDS MODELS;

EID: 79951680329     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-010-0191-2     Document Type: Article

References (39)

1. NIH consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy 2001 Osteoporosis prevention, diagnosis and therapy JAMA 285 785 795 10.1001/jama.285.6.785
2. SL Silverman ME Minshall W Shen KD Harper S Xie 2001 Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from Multiple Outcomes of Raloxifene Evaluation Study Arthritis Rheum 44 2611 2619 1:STN:280:DC%2BD3MnmsFeqsg%3D%3D 10.1002/1529-0131(200111)44:11<2611:: AID-ART441>3.0.CO;2-N 11710717 (Pubitemid 33049339)
3. DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1535 1541 1:CAS:528:DyaK2sXisFCktQ%3D%3D 10.1016/S0140-6736(96)07088-2 8950879 (Pubitemid 26411651)
4. SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor TA Musliner L Palermo R Prineas SM Rubin JC Scott T Vogt R Wallace AJ Yates AZ LaCroix 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 2077 2082 1:CAS:528:DyaK1MXjsVWruw%3D%3D 10.1001/jama.280.24.2077 9875874 (Pubitemid 29014065)
5. ST Harris NB Watts HK Genant CD McKeever T Hangartner M Keller CH Chesnut 3rd J Brown EF Eriksen MS Hoseyni DW Axelrod PD Miller 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group JAMA 282 1344 1352 1:CAS:528:DyaK1MXmvFansr0%3D 10.1001/jama.282.14.1344 10527181 (Pubitemid 29483192)
6. B Ettinger DM Black BH Mitlak RK Knickerbocker T Nickelsen HK Genant C Christiansen PD Delmas JR Zanchetta J Stakkestad CC Glüer K Krueger FJ Cohen S Eckert KE Ensrud LV Avioli P Lips SR Cummings 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 637 645 1:CAS:528:DyaK1MXlvVKqurg%3D 10.1001/jama.282.7.637 10517716 (Pubitemid 29384151)
7. RM Neer CD Arnaud JR Zanchetta R Prince GA Gaich JY Reginster AB Hodsman EF Eriksen S Ish-Shalom HK Genant O Wang BH Mitlak 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434 1441 1:CAS:528:DC%2BD3MXktVSgsbw%3D 10.1056/NEJM200105103441904 11346808 (Pubitemid 32402100)
8. KW Lyles CS Colon-Emeric JS Magaziner JD Adachi CF Pieper C Mautalen L Hyldstrup C Recknor L Nordsletten KA Moore C Lavecchia J Zhang P Mesenbrink PK Hodgson K Abrams JJ Orloff Z Horowitz EF Eriksen S Boonen 2007 The HORIZON recurrent fracture trial. Zoledronic acid and clinical fractures and mortality after hip fracture N Engl J Med 357 1799 1809 1:CAS:528:DC%2BD2sXht1Kit7nN 10.1056/NEJMoa074941 17878149 (Pubitemid 350044800)
9. P Garnero WJ Shih E Gineytes DB Karpf PD Delmas 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment J Clin Endocrinol Metab 79 1693 1700 1:CAS:528:DyaK2MXislWiuro%3D 10.1210/jc.79.6.1693 7989477
10. GY Boivin PM Chavassieux AC Santora J Yates PJ Meunier 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women Bone 27 687 694 1:CAS:528:DC%2BD3cXosFygtL8%3D 10.1016/S8756-3282(00)00376-8 11062357
11. M Saito S Mori T Mashiba S Komatsubara K Marumo 2008 Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs Osteoporos Int 19 1343 1354 1:CAS:528:DC%2BD1cXps1Srsbg%3D 10.1007/s00198-008-0585-3 18373056
12. SY Tang MR Allen R Phipps DB Burr D Vashishth 2009 Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate Osteopors Int 20 887 894 1:CAS:528:DC%2BD1MXls12kt78%3D 10.1007/s00198-008-0754-4
13. SJ Glover R Eastell EV McCloskey A Rogers P Garnero J Lowery R Belleli TM Wright MR John 2009 Rapid and robust response of biochemical markers of bone formation to teriparatide therapy Bone 45 1053 1058 1:CAS:528:DC%2BD1MXhtlGit7bL 10.1016/j.bone.2009.07.091 19679211
14. M Saito K Fujii K Marumo 2006 Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls Calcif Tissue Int 79 160 168 1:CAS:528:DC%2BD28XpvFalsLs%3D 10.1007/s00223-006-0035-1 16969591 (Pubitemid 44440444)
15. M Saito K Marumo S Soshi Y Kida C Ushiku Shinohara 2009 Raloxifene ameliorates detrimental enzymatic and non-enzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia Osteoporos Int 21 655 666 10.1007/s00198-009-0980-4 19484165
16. JB van Meurs RA Dhonukshe-Rutten SM Pluijm M van der Klift R de Jonge J Lindemans LC de Groot A Hofman JC Witteman JP van Leeuwen MM Breteler P Lips HA Pols AG Uitterlinden 2004 Homocysteine levels and the risk of osteoporotic fracture N Engl J Med 350 2033 2041 10.1056/NEJMoa032546 15141041 (Pubitemid 38596554)
17. RR McLean PF Jacques J Selhub KL Tucker EJ Samelson KE Broe MT Hannan LA Cupples DP Kiel 2004 Homocysteine as a predictive factor for hip fracture in older persons N Engl J Med 350 2042 2049 1:CAS:528:DC%2BD2cXktVeis7g%3D 10.1056/NEJMoa032739 15141042 (Pubitemid 38596555)
18. M Shiraki T Urano T Kuroda M Saito S Tanaka M Miyao-Koshizuka S Inoue 2008 The synergistic effect of bone mineral density and methylenetetrahydrofolate reductase (MTHFR) polymorphism (C677T) on fractures J Bone Miner Metab 26 595 602 1:CAS:528:DC%2BD1cXhtlWhtbzP 10.1007/s00774-008- 0878-9 18979159
19. M Shiraki T Kuroda S Tanaka M Saito M Fukunaga T Nakamura 2008 Nonenzymatic collagen cross-links induced by glycation (pentosidine) predicts vertebral fractures J Bone Miner Metab 26 93 100 1:CAS:528:DC%2BD2sXhsVGhurjI 10.1007/s00774-007-0784-6 18095070 (Pubitemid 350307997)
20. M Shiraki Y Shiraki C Aoki T Hosoi S Inoue M Kaneki Y Ouchi 1997 Association of bone mineral density with apolipoprotein E phenotype J Bone Miner Res 12 1438 1445 1:CAS:528:DyaK2sXmt1WksLo%3D 10.1359/jbmr.1997.12.9.1438 9286760 (Pubitemid 27375387)
21. HK Genant M Jergas L Palermo M Nevitt RS Valentin D Black SR Cummings 1996 Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The study of osteoporotic fractures research group J Bone Miner Res 11 984 996 1:STN:280:DyaK28zptVShtA%3D%3D 10.1002/jbmr.5650110716 8797120 (Pubitemid 26200050)
22. H Orimo Y Hayashi M Fukunaga T Sone S Fujiwara M Shiraki K Kushida S Miyamoto S Soen J Nishimura Y Oh-hashi T Hosoi I Gorai H Tanaka T Igai H Kishimoto 2001 Osteoporosis diagnostic criteria for primary osteoporosis: year 2000 revision J Bone Miner Metab 19 331 337 1:STN:280:DC%2BD3MngvFGntw%3D%3D 10.1007/s007740170001 11685647 (Pubitemid 33041725)
23. K Yoshihara K Nakamura M Kanai Y Nagayama S Takahashi N Saito M Nagata 1998 Determination of urinary and serum pentosidine and its application to elder patients Biol Pharm Bull 21 1005 1008 1:CAS:528:DyaK1cXntVSltbk%3D 9821800 (Pubitemid 28513973)
24. B Vester K Rasmussen 1991 High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum Eur J Clin Chem Clin Biochem 29 549 554 1:CAS:528:DyaK38XhslyktQ%3D%3D 1760484
25. SR Cummings DB Karpf F Harris HK Genant K Ensrud AZ LaCroix DM Black 2002 Improvement in spine bone mineral density and reduction in risk of vertebral fractures during the treatment with antiresorptive drugs Am J Med 112 281 289 1:CAS:528:DC%2BD38XhvVWkurk%3D 10.1016/S0002-9343(01)01124-X 11893367 (Pubitemid 34219441)
26. PD Delmas E Seeman 2004 Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy Bone 34 599 604 1:CAS:528:DC%2BD2cXisF2ntL4%3D 10.1016/j.bone.2003.12. 022 15050889 (Pubitemid 38393794)
27. Bell KJL, Hayen A, Macaskill P, Irwing L, Craig JC, Ensrud K, Bauer DC (2009) Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. Br Med J338:b2266. doi: 10.1136/bjm.b2266
28. M Shiraki T Kuroda T Nakamura M Fukunaga T Hosoi H Orimo K Makino 2006 The sample size required for intervention studies on fracture prevention can be decreased by using a bone resorption marker in the inclusion criteria: prospective study of a subset of the Nagano Cohort, on behalf of the Adequate Treatment of Osteoporosis (A-TOP) Research Group J Bone Miner Metab 24 219 225 10.1007/s00774-005-0675-7 16622735
29. R Eastell I Barton RA Hannon A Chines P Garnero PD Delmas 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate J Bone Miner Res 18 1051 1056 1:CAS:528: DC%2BD3sXkslOhsb0%3D 10.1359/jbmr.2003.18.6.1051 12817758 (Pubitemid 37294942)
30. MJ Seibel V Naganathan I Barton A Grauer 2004 Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate J Bone Miner Res 19 323 329 1:CAS:528:DC%2BD2cXhs1elsrs%3D 10.1359/JBMR.0301231 14969403 (Pubitemid 38116747)
31. M Saito K Marumo 2010 Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus Osteoporos Int 21 195 214 1:CAS:528:DC%2BC3cXjtl2ntg%3D%3D 10.1007/s00198-009-1066-z 19760059
32. AV Schwartz P Garnero TA Hillier DE Sellmeyer ES Strotmeyer KR Feingold HE Resnick FA Tylavsky DM Black SR Cummings TB Harris DC Bauer for the Health, Aging, Body Composition study 2009 Pentosidine and increased fracture risk in older adults with type 2 diabetes J Clin Endocrinol Metab 94 2380 2386 1:CAS:528:DC%2BD1MXosl2ksr8%3D 10.1210/jc.2008-2498 19383780
33. M Yamamoto T Yamaguchi M Yamauchi S Yano T Sugimoto 2008 Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes J Clin Endocrinol Metab 93 1013 1019 1:CAS:528:DC%2BD1cXjsFymsrc%3D 10.1210/jc.2007-1270 18160470 (Pubitemid 351398587)
34. D Vashishth 2007 The role of the collagen matrix in skeletal fragility Curr Osteoporos Rep 5 62 66 10.1007/s11914-007-0004-2 17521507 (Pubitemid 46954743)
35. X Wang X Shen X Li CM Agrawal 2002 Age-related changes in the collagen network and toughness of bone Bone 31 1 7 10.1016/S8756-3282(01)00697-4 12110404 (Pubitemid 34754417)
36. P Garnero O Borel E Gineyts F Duboeuf H Solberg ML Bouxsein C Christiansen PD Delmas 2006 Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone Bone 38 300 309 1:CAS:528:DC%2BD28Xhslyrt70%3D 10.1016/j.bone.2005.09.014 16271523 (Pubitemid 43255423)
37. M Saito K Fujii S Sohshi T Tanaka 2006 Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation induced pentosidine in the femoral neck cortex in cases of femoral neck fracture Osteoporos Int 17 986 995 1:CAS:528:DC%2BD28XltlOju74%3D 10.1007/s00198-006- 0087-0 16552468 (Pubitemid 43864852)
38. E Gineyts F Munoz C Bertholon E Sornay-Rendu R Chapurlat 2010 Urinary levels of pentosidine and risk of fracture in post menopausal women: the OFELY study Osteoporos Int 21 243 250 1:CAS:528:DC%2BC3cXjtl2nsA%3D%3D 10.1007/s00198-009-0939-5 19421701
39. P Odetti S Rossi F Monacelli A Poggi M Cirnigliaro M Federici A Federici 2005 Advanced glycation end products and bone loss during aging Ann N Y Acad Sci 1043 710 717 1:CAS:528:DC%2BD2MXpvVKqurk%3D 10.1196/annals.1333.082 16037297 (Pubitemid 41123964)